4:41 PM
 | 
Oct 14, 2013
 |  BC Extra  |  Clinical News

Coronado falls after whipworm product misses in Crohn's

Coronado Biosciences Inc. (NASDAQ:CNDO) fell $3.86 (67%) to $1.91 on Monday after reporting that Trichuris suis ova (TSO) missed the primary endpoint of induction of response at week 12 vs. placebo in the 250-patient Phase II TRUST-I trial to treat Crohn's...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >